bpc 157 symptoms What to Know About Peptides the FDA Is Considering for Use The Hidden Risks of BPC‑157:

The parent compound exists naturally in human gastric juice as part of a much larger protein weighing approximately 40,000 daltons

The FDA found no clinical studies or publicly available human exposure data for administered MOTS-c, no adequate toxicology, uncertain characterisation and unresolved immunogenicity.[6] The same caution applies to a large range of other non-GLP-1-related peptides that are promoted well beyond the supporting human evidence and in the absence of adequate safety data.[8] Unapproved peptides are not included in the Australian Register of Therapeutic Goods and have not been evaluated by the TGA for safety, quality or effectiveness

So, its not surprising that a biohack like peptides, which promises quick results, might appeal to them

It is given subcutaneously